Aileron Therapeutics, Inc (ALRN)

Etorro trading 970x250

About Aileron Therapeutics, Inc

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company’s lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts. Address: 290 Pleasant Street, Watertown, MA, United States, 02472

Aileron Therapeutics, Inc News and around…

Latest news about Aileron Therapeutics, Inc (ALRN) common stock and company :

Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
15 Aug, 2022 Yahoo! Finance

Company continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer clinical trialExtended cash runway expected to support operations through end of 1Q 2024Presented new data at the Society for Investigational Dermatology 2022 Annual Meeting suggesting ALRN-6924’s potential to protect against chemotherapy-induced alopeciaReported new data from healthy volunteer study demonstrating ALRN-6924-induced cell cycle

Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
09 Aug, 2022 FinancialContent

Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. TOP Financial ...

12 Health Care Stocks Moving In Monday's Intraday Session
08 Aug, 2022 FinancialContent

Gainers Karuna Therapeutics (NASDAQ:KRTX) shares increased by 63.5% to $229.46 during Monday's regular session. As ...

Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session
08 Aug, 2022 FinancialContent

Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The ...

12 Health Care Stocks Moving In Friday's After-Market Session
05 Aug, 2022 FinancialContent

Gainers Aileron Therapeutics (NASDAQ:ALRN) shares rose 27.9% to $0.22 during Friday's after-market session. This security traded at a ...

Why Is Marker Therapeutics Trading Higher By 119%: Here Are 42 Stocks Moving Premarket
05 Aug, 2022 FinancialContent

Gainers Assure Holdings Corp. (NASDAQ: IONM) shares rose 141.4% to $5.07 in pre-market trading after jumping around 104% on ...

Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday
03 Aug, 2022 FinancialContent

Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese ...

Stocks That Hit 52-Week Lows On Tuesday
02 Aug, 2022 FinancialContent

Tuesday's session saw 63 companies set new 52-week lows. Noteable 52-Week Lows: The largest company by market cap ...

Why Applied DNA Sciences Is Trading Higher By 166%, Here Are 75 Stocks Moving In Tuesday's Mid-Day Session
02 Aug, 2022 FinancialContent

Gainers AMTD IDEA Group (NYSE: AMTD) shares jumped 284% to $8.00 after jumping 18% on Monday. The company owns 90%+ of AMTD ...

Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
02 Aug, 2022 FinancialContent

Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around ...

Stocks That Hit 52-Week Lows On Monday
01 Aug, 2022 FinancialContent

On Monday, 92 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
01 Aug, 2022 FinancialContent

Gainers Celyad Oncology (NASDAQ:CYAD) stock increased by 45.0% to $2.48 during Monday's pre-market session. The ...

Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer
01 Aug, 2022 Yahoo! Finance

Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mutated breast cancerKey protocol enhancements include: Selection of 1.2 mg/kg dose of ALRN-6924 with the goal to extend duration of cell cycle arrest and, thus, chemoprotectionNew primary endpoint that is more closely aligned with regulatory preced

Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
15 Jul, 2022 FinancialContent

Gainers United Maritime Corporation (NASDAQ: USEA) shares jumped 180.9% to $6.19. United Maritime, on Tuesday, announced ...

Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022
08 Jul, 2022 Yahoo! Finance

BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand beginning Monday, July 11, 2022. Management will be availabl

Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
01 Jul, 2022 FinancialContent

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. ...

This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
30 Jun, 2022 FinancialContent

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
29 Jun, 2022 FinancialContent

Gainers Allena Pharma (NASDAQ:ALNA) stock moved upwards by 166.4% to $0.32 during Wednesday's regular session. Trading volume for ...

Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session
29 Jun, 2022 FinancialContent

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its ...

Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting
29 Jun, 2022 FinancialContent

Aileron Therapeutics(NASDAQ: ALRN)announced interim datafrom its Phase 1b chemoprotection trial of patients with ...

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
29 Jun, 2022 Yahoo! Finance

Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between treatment arms may have introduced a bias against ALRN-6924 on the composite primary endpoint Evaluating cycles 1-6, the imbalance increases further (79% of cycles on ALRN-6924 versus 57% on placebo) Interim finding on the trial’s composite primary endpoint, which was the proportion of treatment cyc

Aileron Treats First Patient With ALRN-6924 In Breast Cancer Setting
19 May, 2022 FinancialContent

Aileron Therapeutics (NASDAQ: ALRN) enrolled the first patients in its Phase 1b clinical trial evaluating ALRN-6924 for bone marrow in ...

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
19 May, 2022 Yahoo! Finance

Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicitiesTrial is evaluating ALRN-6924 as a treatment to prevent chemotherapy-induced neutropenia, other bone marrow toxicities, and toxicities outside of the bone marrow in patients with p53-mutated breast cancer being treated with doxorubicin plus cyclophosphamide and docetaxel (AC+D)AC+D is a highly toxic chemotherapy regimen, causing severe neutropenia i

3 Oversold Biotech Stocks to Buy Now
19 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Looking for oversold biotech stocks? These three have all seen significant drops this year despite promising catalysts for the future. The post 3 Oversold Biotech Stocks to Buy Now appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference
17 May, 2022 Yahoo! Finance

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. ET in Miami, FL. A live webcast of the event will be available under the In

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022
13 May, 2022 Yahoo! Finance

BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will host a virtual KOL investor event on Thursday, May 19, 2022, at 4:00 pm ET/ 1:00 pm PT. The virtual event will feature presentations from the company's President and Chief Executive Officer, Manuel Aivado, M.D., Ph.D., as well as key opinion leaders, Ralf Paus,

Will Aileron Therapeutics (NASDAQ:ALRN) Spend Its Cash Wisely?
11 May, 2022 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting
10 May, 2022 Yahoo! Finance

Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia)New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicles and their stem cellsALRN-6924-induced cell cycle arrest protected hair follicles from paclitaxel-induced toxicity and irreversible stem cell damageAileron’s precision medicine-based approach is designed to selectively protect normal, healthy cells

Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
05 May, 2022 Yahoo! Finance

On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in June 2022; topline results anticipated in 4Q 2022On track to initiate Phase 1b clinical trial of ALRN-6924 in patients with p53-mutated ER+/HER2- neoadjuvant breast cancer in 2Q 2022; initial interim results anticipated in 4Q 2022Company to host a virtual investor event on May 19th to discuss ALRN-6924’s revolutionary potential as the first prec

Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year?
21 Apr, 2022 Yahoo! Finance

Here is how Aileron Therapeutics, Inc. (ALRN) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.

Aileron Therapeutics, Inc (ALRN) is a NASDAQ Common Stock listed in , ,

970x250